Literature DB >> 7695314

Survey of in vitro susceptibilities of Vibrio cholerae O1 and O139 to antimicrobial agents.

T Yamamoto1, G B Nair, M J Albert, C C Parodi, Y Takeda.   

Abstract

Vibrio cholerae O139 (173 strains) and O1 (221 strains) were tested for their in vitro susceptibilities to 39 antimicrobial agents. Both O139 and O1 strains were highly susceptible to azithromycin, cephems, minocycline, penems, and newer fluoroquinolones. O139 strains (94.8%), O1 Indian El Tor strains (97%), and Bangladeshi El Tor strains (50%) were highly resistant to streptomycin, sulfamethoxazole, and trimethoprim and moderately resistant to chloramphenicol and furazolidone, in sharp contrast to O1 Peruvian El Tor and O1 classical strains. Some Bangladeshi El Tor strains (43.3%) showed tetracycline resistance as well.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7695314      PMCID： PMC162516          DOI： 10.1128/AAC.39.1.241

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Transduction of linked genetic characters of the host by bacteriophage P1.

Authors:  E S LENNOX
Journal:  Virology       Date:  1955-07       Impact factor: 3.616

2.  Studies on penem antibiotics. II. In vitro activity of SUN5555, a new oral penem.

Authors:  T Nishino; Y Maeda; E Ohtsu; S Koizuka; T Nishihara; H Adachi; K Okamoto; M Ishiguro
Journal:  J Antibiot (Tokyo)       Date:  1989-06       Impact factor: 2.649

Review 3.  Synthesis and antimicrobial spectrum of FCE 22101 and its orally available ester FCE 22891.

Authors:  G Franceschi; E Perrone; M Alpegiani; A Bedeschi; C Battistini; F Zarini; C Della Bruna
Journal:  J Antimicrob Chemother       Date:  1989-03       Impact factor: 5.790

Review 4.  Genetic and physical map of plasmid NR1: comparison with other IncFII antibiotic resistance plasmids.

Authors:  D D Womble; R H Rownd
Journal:  Microbiol Rev       Date:  1988-12

5.  Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.

Authors:  J Retsema; A Girard; W Schelkly; M Manousos; M Anderson; G Bright; R Borovoy; L Brennan; R Mason
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

6.  Studies on penem antibiotics. I. Synthesis and in vitro activity of novel 2-chiral substituted penems.

Authors:  M Ishiguro; H Iwata; T Nakatsuka; R Tanaka; Y Maeda; T Nishihara; T Noguchi; T Nishino
Journal:  J Antibiot (Tokyo)       Date:  1988-11       Impact factor: 2.649

7.  Rapid procedure for detection and isolation of large and small plasmids.

Authors:  C I Kado; S T Liu
Journal:  J Bacteriol       Date:  1981-03       Impact factor: 3.490

8.  Controlled comparison of tetracycline and furazolidone in cholera.

Authors:  N F Pierce; J G Banwell; R C Mitra; G J Caranasos; R I Keimowitz; J Thomas; A Mondal
Journal:  Br Med J       Date:  1968-08-03

9.  Comparative antibacterial activity of the penem ALP 201.

Authors:  T Bergan; J da Fonseca
Journal:  Chemotherapy       Date:  1991       Impact factor: 2.544

Review 10.  Erythromycin: a microbial and clinical perspective after 30 years of clinical use (2).

Authors:  J A Washington; W R Wilson
Journal:  Mayo Clin Proc       Date:  1985-04       Impact factor: 7.616
View more
  12 in total

1.  Plasmidic extended-spectrum beta-lactamases in Vibrio cholerae O1 El Tor isolates in Argentina.

Authors:  Alejandro Petroni; Alejandra Corso; Roberto Melano; María Luisa Cacace; Ana María Bru; Alicia Rossi; Marcelo Galas
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Emergence of fluoroquinolone-resistant strains of Vibrio cholerae O1 biotype El Tor among hospitalized patients with cholera in Calcutta, India.

Authors:  P Garg; S Sinha; R Chakraborty; S K Bhattacharya; G B Nair; T Ramamurthy; Y Takeda
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

3.  Emergence of fluoroquinolone resistance in strains of Vibrio cholerae isolated from hospitalized patients with acute diarrhea in Calcutta, India.

Authors:  A K Mukhopadhyay; I Basu; S K Bhattacharya; M K Bhattacharya; G B Nair
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

4.  Antibiotic resistance and plasmid profile of environmental isolates of Vibrio species from Mai Po Nature Reserve, Hong Kong.

Authors:  Yanling Wang; P C Leung; Pei-Yuan Qian; Ji-Dong Gu
Journal:  Ecotoxicology       Date:  2006-05-06       Impact factor: 2.823

Review 5.  Cholera.

Authors:  Jason B Harris; Regina C LaRocque; Firdausi Qadri; Edward T Ryan; Stephen B Calderwood
Journal:  Lancet       Date:  2012-06-30       Impact factor: 79.321

6.  Temporal shifts in traits of Vibrio cholerae strains isolated from hospitalized patients in Calcutta: a 3-year (1993 to 1995) analysis.

Authors:  A K Mukhopadhyay; S Garg; R Mitra; A Basu; K Rajendran; D Dutta; S K Bhattacharya; T Shimada; T Takeda; Y Takeda; G B Nair
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

7.  Reduced expression of the vca0421 gene of Vibrio cholerae O1 results in innate resistance to ciprofloxacin.

Authors:  Jun Okuda; Naoki Hayashi; Yuka Wakahara; Naomasa Gotoh
Journal:  Antimicrob Agents Chemother       Date:  2010-08-30       Impact factor: 5.191

8.  Role of active efflux in association with target gene mutations in fluoroquinolone resistance in clinical isolates of Vibrio cholerae.

Authors:  Somesh Baranwal; Keya Dey; T Ramamurthy; G Balakrish Nair; Manikuntala Kundu
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  Vitek system antimicrobial susceptibility testing of O1, O139, and non-O1 Vibrio cholerae.

Authors:  C V Sciortino; J A Johnson; A Hamad
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

10.  SXT constin among Vibrio cholerae isolates from a tertiary care hospital.

Authors:  Kavita Pande; Deepak Kumar Mendiratta; Deotale Vijayashri; Dipak C Thamke; Pratibha Narang
Journal:  Indian J Med Res       Date:  2012-03       Impact factor: 2.375
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.